This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tuesday's Small-Cap Winners & Losers

Small-cap stocks underperformed the major indices for the second straight session, as several small health care names took their lumps.

Drugmaker Acusphere (ACUS), of Watertown, Mass., lost 11% to $2.26, after agreeing to sell $20 million in stock and warrants to institutional investors under an existing shelf registration. Net proceeds are expected at around $18.7 million.

Geron (GERN) also took a hit after failing to announce big news on its GRN163L cancer treatment. The California-based company only reported that phase I/II testing has yielded positive results in pharmacokinetics and tolerability. Shares tumbled 8.5% to $7.97.

Cyberonics (CYBX), which makes devices for epilepsy treatment, slid 7.8% to $16.59 on disappointing financials. The Houston-based company's loss more than doubled to 42 cents a share -- 7 cents worse than the mean Street target from Thomson Financial. Revenue came in just shy of consensus.

Geron and Cyberonics pressured the Russell 2000, which was recently off 0.9%, or 7.83 points, to 825.35.

But a few other Russell 2000 components -- namely, Pier 1 Imports (PIR), Robbins & Myers (RBN) and Take-Two Interactive Software (TTWO) -- jumped on analyst upgrades.

Goldman Sachs raised home-furnishings retailer Pier 1 to buy from hold, saying a turnaround might be around the corner. Ohio's Robbins, which makes equipment and systems for a variety of industries, was likewise upped to buy at KeyBanc Capital Market. And Take-Two was upgraded by both JPMorgan and Kaufman Brothers on the heels of last night's earnings report.

Pier 1, Robbins and New York-based Take-Two were all recently trading up 4.7% or more, the latter two in support of the S&P SmallCap 600. Still, the index was down 0.8% at 428.35.

Elsewhere in positive territory, VirtualScopics (VSCP), of Rochester, N.Y., soared 24% to $1.40, after inking a five-year clinical-trials-services deal with a "leading" biotech company. Financial terms weren't disclosed.

Filtration-products maker MFRI (MFRI) quintupled its first-quarter per-share earnings compared with the year-ago period. The company reported earnings of 15 cents a share, beating two analysts' estimates by a nickel. And Georgia's Exide Technologies (XIDE) sharply narrowed its fiscal fourth-quarter loss to 35 cents a share. A year ago, the lead-acid-batteries maker lost $2.98 a share.

Shares of Illinois-based MFRI were leaping $3.12, or 13%, to $26.52. Exide advanced 8.1% to $8.25.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,914.21 +109.41 0.61%
S&P 500 2,072.86 +2.21 0.11%
NASDAQ 4,775.2910 +9.9110 0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs